Reva Medical IPO Will Fund ReZolve Bioresorbable Stent Study In Early 2011

Reva Medical's ReZolve bioresorbable drug-eluting stent is set to enter a pilot clinical study in the first quarter of 2011, funded by a planned $63 million initial public stock offering, the company says